应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NVS 诺华
盘后交易 03-10 19:00:12 EDT
161.59
-1.20
-0.74%
盘后
161.33
-0.26
-0.16%
17:40 EDT
最高
163.07
最低
160.43
成交量
370.57万
今开
161.35
昨收
162.79
日振幅
1.62%
总市值
3,083亿
流通市值
2,934亿
总股本
19.08亿
成交额
6.00亿
换手率
0.20%
流通股本
18.16亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
诺和诺德、诺华、强生、默沙东等“集体豪赌”,口服生物药这么难还要砸?
MedTrend医趋势 · 02-27
诺和诺德、诺华、强生、默沙东等“集体豪赌”,口服生物药这么难还要砸?
诺华制药拟在德州新建放射性配体疗法生产基地
格隆汇 · 02-25
诺华制药拟在德州新建放射性配体疗法生产基地
海量财经|诺华CEO2.3亿年薪背后:一场业绩、股价与长期价值的精密对赌
海报新闻 · 02-25
海量财经|诺华CEO2.3亿年薪背后:一场业绩、股价与长期价值的精密对赌
【市场】17个国谈药拟进院,独家品种霸屏
米内网 · 02-25
【市场】17个国谈药拟进院,独家品种霸屏
诺华同意以144.6亿卢比向投资财团出售印度子公司70.68%的股份
环球市场播报 · 02-20
诺华同意以144.6亿卢比向投资财团出售印度子公司70.68%的股份
产业新闻 | 礼来单抗/多肽药物组合达3期临床主要终点;穿越血脑屏障!新锐推进新一代阿尔茨海默病疗法……
药明康德 · 02-19
产业新闻 | 礼来单抗/多肽药物组合达3期临床主要终点;穿越血脑屏障!新锐推进新一代阿尔茨海默病疗法……
超级大洗牌!跨国药企中国市场最新排名
健识局 · 02-16
超级大洗牌!跨国药企中国市场最新排名
诺华制药2025财年实现净利润140.56亿美元,同比增加17.78%
市场透视 · 02-07
诺华制药2025财年实现净利润140.56亿美元,同比增加17.78%
诺华制药(NVS.US)全球首创自免新药在中国申报上市
智通财经 · 02-06
诺华制药(NVS.US)全球首创自免新药在中国申报上市
诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心
澎湃新闻 · 02-05
诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心
仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑
智通财经 · 02-04
仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑
诺华:Q4核心净利润38.9亿美元,高于预期
格隆汇 · 02-04
诺华:Q4核心净利润38.9亿美元,高于预期
诺华可善挺(司库奇尤单抗)放射学阴性中轴型脊柱关节炎(nr-axSpA)适应症在华获批
每日经济新闻 · 02-03
诺华可善挺(司库奇尤单抗)放射学阴性中轴型脊柱关节炎(nr-axSpA)适应症在华获批
诺华制药(NVS.US)siRNA疗法“英克司兰”获批新适应症
智通财经 · 01-28
诺华制药(NVS.US)siRNA疗法“英克司兰”获批新适应症
财报前瞻|诺华本季度营收预计增5.72%,机构观点以偏积极为主
财报Agent · 01-28
财报前瞻|诺华本季度营收预计增5.72%,机构观点以偏积极为主
直击达沃斯丨医渡科技(02158)、文莱卫生部、诺华基金会宣布启动AI驱动的国家级心血管疾病防控项目
智通财经 · 01-23
直击达沃斯丨医渡科技(02158)、文莱卫生部、诺华基金会宣布启动AI驱动的国家级心血管疾病防控项目
FDA概述细胞/基因疗法CMC灵活性 可能对诺华与辉瑞有利
环球市场播报 · 01-14
FDA概述细胞/基因疗法CMC灵活性 可能对诺华与辉瑞有利
赛诺神经与诺华签署17亿美元许可协议 合作开发阿尔茨海默病治疗药物
环球市场播报 · 01-12
赛诺神经与诺华签署17亿美元许可协议 合作开发阿尔茨海默病治疗药物
中晟全肽与诺华就一款放射性配体疗法资产签署全球授权协议
每日经济新闻 · 01-12
中晟全肽与诺华就一款放射性配体疗法资产签署全球授权协议
超1亿美元!蛋白降解剂“吸金”,强生、诺华、谷歌都来了
医药魔方 · 01-09
超1亿美元!蛋白降解剂“吸金”,强生、诺华、谷歌都来了
加载更多
公司概况
公司名称:
诺华
所属市场:
NYSE
上市日期:
--
主营业务:
Novartis AG于1996年2月29日根据瑞士法律注册成立,为股份公司。公司是一家创新医药公司,从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域,包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。
发行价格:
--
{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":161.59,"timestamp":1773172800000,"preClose":162.79,"halted":0,"volume":3705705,"hourTrading":{"tag":"盘后","latestPrice":161.3273,"preClose":161.59,"latestTime":"17:40 EDT","volume":17628,"amount":2848619.04756,"timestamp":1773178835875,"change":-0.2627,"changeRate":-0.001626,"amplitude":0.020391},"delay":0,"changeRate":-0.0073714601634006305,"floatShares":1816000000,"shares":1907999999,"eps":7.15,"marketStatus":"盘后交易","change":-1.2,"latestTime":"03-10 19:00:12 EDT","open":161.35,"high":163.07,"low":160.43,"amount":599914877.8257,"amplitude":0.016217,"askPrice":162.5,"askSize":200,"bidPrice":161,"bidSize":100,"shortable":3,"etf":0,"ttmEps":7.15,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773187200000},"marketStatusCode":4,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":162.79,"dividendRate":0.024682,"preHourTrading":{"tag":"盘前","latestPrice":161.2,"preClose":162.79,"latestTime":"09:29 EDT","volume":12974,"amount":2102069.5358,"timestamp":1773149370097,"change":-1.59,"changeRate":-0.009767,"amplitude":0.013883},"postHourTrading":{"tag":"盘后","latestPrice":161.3273,"preClose":161.59,"latestTime":"17:40 EDT","volume":17628,"amount":2848619.04756,"timestamp":1773178835875,"change":-0.2627,"changeRate":-0.001626,"amplitude":0.020391},"volumeRatio":1.219124,"optionData":{"bulkOrders":[{"symbol":"NVS","call":true,"expireDate":1776398400000,"strike":"145.0","timestamp":1773171988263,"price":14.7,"volume":24550,"amount":36088500,"type":"-"},{"symbol":"NVS","call":true,"expireDate":1776398400000,"strike":"135.0","timestamp":1773171988263,"price":26.63,"volume":23180,"amount":61728340,"type":"+"}]},"impliedVol":0.284,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2614856698","title":"诺和诺德、诺华、强生、默沙东等“集体豪赌”,口服生物药这么难还要砸?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856698","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856698?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:44","pubTimestamp":1772189087,"startTime":"0","endTime":"0","summary":"2月25日,诺和诺德宣布与麻省理工学院传奇科学家Robert Langer实验室分拆公司Vivtex达成深度合作,交易总额最高达21亿美元,共同开发下一代代谢类药物的口服递送技术。2019年,诺和诺德Rybelsus在美获批上市,成为全球首个口服GLP-1受体激动剂。截至2025年底,其累计销售额已突破百亿美元量级,足以证明口服生物药的巨大潜力。人体本能地阻止大分子进入体内,这是生理保护机制。高盛预测,到2030年口服减重药将占据接近四分之一的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0034235303.USD","LU2023250504.SGD","LU1196500208.SGD","LU1244550577.SGD","LU0154236417.USD","LU0912757837.SGD","LU1093756168.USD","IE00BVYPNV92.GBP","LU0234572021.USD","LU0466842654.USD","LU0792757196.USD","LU1929549753.HKD","SG9999014575.USD","LU1506573853.SGD","NVOX","01276","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","BK4578","LU0985320562.USD","LU0432979614.USD","IE00B3T34201.USD","LU0889566641.SGD","IE00BVYPNW00.USD","LU2471134523.USD","LU1917777945.USD","LU0345769631.USD","LU0795875086.SGD","LU1035773651.USD","IE00BJT1NW94.SGD","LU1201861249.SGD","LU1935042991.SGD","LU2430703251.USD","IE00BLSP4452.SGD","MRK","IE000M9KFDE8.USD","IE00B4R5TH58.HKD","LU2324357040.USD","LU1934455277.USD","LU0980610538.SGD","LU0211331839.USD","LU0266013472.USD","LU0965509283.SGD","LU0106261372.USD","LU1032466523.USD","LU1496350502.SGD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU2129689605.HKD","LU1718418525.SGD","LU0683600562.USD","LU1244550494.USD","LU1732800096.USD","LU0648001328.SGD","LU2471134952.CNY","LU1778281490.HKD","LU1066053197.SGD","JNJ","LU2461242641.AUD","SG9999002232.USD","LU1674673428.USD","BK4533","IE00B2B36J28.USD","LU0006306889.USD","LU1066051225.USD","BK4516","IE00B19Z3581.USD","LU0234570918.USD","LU2602419157.SGD","BK4534","BK4532","LU2125154778.USD","LU1934455194.USD","LU2133065610.SGD","LU0787776722.HKD","BK4599","IE00B42XCP33.USD","IE0009355771.USD","LU0795875169.SGD","LU0203345920.USD","LU1074936037.SGD","LU2471134796.USD","LU2471134879.HKD","SG9999014559.SGD","BK4007","LU2361044865.SGD","LU1934455863.HKD","LU0689626769.HKD","LU0640476718.USD","LU1571399168.USD","LU1989771016.USD","LU0320765489.SGD","LU2089984988.USD","LU0965509101.SGD","LU1894683264.USD","BK4568","LU1983299246.USD","IE00BGHQF631.EUR","IE00BLSP4239.USD","LU0882574055.USD","IE0002141913.USD","LU2129689514.USD","LU1066051498.USD","LU2361045086.USD","LU0238689110.USD","LU1032955483.USD","LU1116320737.USD","LU2361044949.HKD","NVO","LU0070302665.USD","LU1585245621.USD","LU1057294990.SGD","LU0070217475.USD","LU0122379950.USD","LU1732799900.SGD","LU0345770308.USD","LU1941712264.USD","SG9999015341.SGD","LU0124676726.USD","LU2347655156.SGD","LU0130517989.USD","BK4550","SG9999015358.SGD","LU1914381329.SGD","IE00BKVL7J92.USD","LU0208291251.USD","LU0345770993.USD","BK4581","IE00BFTCPJ56.SGD","NVS","BK4504","LU2360032135.SGD","LU2750360641.GBP","LU1093756325.SGD","LU0345769128.USD","LU1699723380.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU0477156953.USD","IE0002270589.USD","LU2505996509.AUD","LU1261432733.SGD","LU2106854487.HKD","LU1941712348.USD","LU1221951046.USD","IE00BDGV0183.EUR","LU1974910355.USD","SG9999002224.SGD","IE00BSNM7G36.USD","BK4559","LU2023250843.SGD","LU0114720955.EUR","LU2430703095.HKD","LU2750360997.AUD","LU1674673691.USD","IE00BN8TJ469.HKD","NVOH","LU1059921491.USD","LU2125154935.USD","LU0058720904.USD","LU0320765646.SGD","LU1894683348.USD","SG9999001176.USD","LU1221951129.SGD","LU1116320901.HKD","LU1061106388.HKD","LU2129689431.USD","LU0289739699.SGD","SG9999014567.USD","LU0965509010.AUD","LU1267930813.SGD","BK4592","LU0130102774.USD","LU1037948541.HKD","LU1069347547.HKD","IE00B7SZLL34.SGD","IE00BBT3K403.USD","LU2430703178.SGD","SG9999014542.SGD","LU0098860793.USD","LU1162221912.USD","LU1430594728.SGD","LU0265550359.USD","LU2505996681.GBP","SG9999013999.USD","BK4588","IE00BFXG1179.USD","SG9999001176.SGD","LU1989772923.USD","LU2592432038.USD","SG9999001440.SGD","LU0265550946.USD","LU1023059063.AUD","LU0861579265.USD","LU1280957306.USD","LU2112291526.USD","LU1244550221.USD","LU2468319806.SGD","SGXZ57979304.SGD","LU0203347892.USD","LU0965508806.USD","BK4585","LU1291159041.SGD","IE00B3PB1722.GBP","LU1989772840.SGD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2614308246","title":"诺华制药拟在德州新建放射性配体疗法生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308246","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614308246?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:02","pubTimestamp":1772024578,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVS","BK4532","BK1574","BK4585","LU0320765489.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4578","IE00B2B36J28.USD","LU0208291251.USD","LU0211331839.USD","01477","BK4588","IE0009355771.USD","BK1191","IE00B4R5TH58.HKD","BK4007"],"gpt_icon":0},{"id":"2614428702","title":"海量财经|诺华CEO2.3亿年薪背后:一场业绩、股价与长期价值的精密对赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614428702","media":"海报新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614428702?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:22","pubTimestamp":1772011353,"startTime":"0","endTime":"0","summary":"全球医药行业的聚光灯,在2026年初悄然转向瑞士巴塞尔。跨国制药巨头诺华发布2025财年业绩,全球净销售额545.32亿美元,同比增长8%;营业收入176.44亿美元,同比大增25%,核心营业利润率突破40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602253654131088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4578","LU0211331839.USD","BK4588","IE00B2B36J28.USD","BK4532","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4585","LU0320765489.SGD","BK4007","LU0208291251.USD","NVS","IE0002141913.USD"],"gpt_icon":0},{"id":"2614554709","title":"【市场】17个国谈药拟进院,独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日,成都市第六人民医院发布招标公示,将组织拟引入药品生产企业遴选工作。17个新药在列,均为国谈药,涵盖化学药及生物药,既有环泊酚注射液等超10亿大品种,亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药,目前均已纳入国家医保乙类目录,主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域,可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002653","BK4599","002793","NVOH","LU1093756168.USD","600276","IE00BZ1G4Q59.USD","NVO","NVOX","NVS","BK4532","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","BK4585","BK4588","01276","LU0154236417.USD"],"gpt_icon":1},{"id":"2612293950","title":"诺华同意以144.6亿卢比向投资财团出售印度子公司70.68%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2612293950","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612293950?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:37","pubTimestamp":1771601820,"startTime":"0","endTime":"0","summary":"诺华 已同意将其在诺华印度有限公司持有的70.68%股份,以144.6亿卢比的价格,出售给由WaveRise Investments、ChrysCapital Fund X和Two Infinity Partners组成的投资财团,从而有效结束了其在2024年2月宣布的战略评估。此次评估聚焦于这家在印度上市的子公司,该公司负责销售处方药、仿制药和非处方药。市场反应迅速:在孟买交易中,诺华印度股价一度上涨19.3%,至996.50卢比,交易价格高于公开要约收购价。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnnsse2737863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","IE0002141913.USD","LU0208291251.USD","LU0320765489.SGD","BK4007","MNDmain","BK4588","BK4532","BK4585","BK4578","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","NVS","LU0211331839.USD"],"gpt_icon":0},{"id":"2612147565","title":"产业新闻 | 礼来单抗/多肽药物组合达3期临床主要终点;穿越血脑屏障!新锐推进新一代阿尔茨海默病疗法……","url":"https://stock-news.laohu8.com/highlight/detail?id=2612147565","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612147565?lang=zh_cn&edition=full","pubTime":"2026-02-19 07:30","pubTimestamp":1771457447,"startTime":"0","endTime":"0","summary":"礼来单抗/多肽药物组合达3期临床主要终点礼来今日宣布,TOGETHER-PsO临床3b期研究取得积极顶线结果。安全性方面,联合用药相关不良事件总体为轻至中度,与两种药物既往已知安全性特征一致。新锐推进潜在“best-in-class”阿尔茨海默病疗法Korsana Biosciences今日宣布结束隐匿模式并公开亮相。此次合作将整合UNP以人工智能增强的大环肽分子平台与诺华在全球药物开发及商业化方面的能力,共同开发下一代治疗药物,潜在应用方向包括心血管疾病领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0198837287.USD","IE00BK4W5L77.USD","LU2471134523.USD","LU2471134952.CNY","LU2360106947.USD","LU2491050071.SGD","LU2750360997.AUD","LU2552382215.SGD","IE00BJJMRZ35.SGD","BK4534","LU1548497426.USD","LU2023251221.USD","LU1057294990.SGD","LU0466842654.USD","LU0097036916.USD","LU2491049909.HKD","SGXZ31699556.SGD","LU0114720955.EUR","LU2111349929.HKD","LU0203202063.USD","GB00BDT5M118.USD","SGXZ81514606.USD","LU2361044949.HKD","LU1989771016.USD","IE0004445239.USD","LU0820561909.HKD","LU2756315664.SGD","ELIS","IE00BJJMRX11.SGD","IE00B1BXHZ80.USD","IE00B2B36J28.USD","SGXZ99366536.SGD","LU1127390331.HKD","IE00BFTCPJ56.SGD","LU2471134879.HKD","SG9999014914.USD","LU2324357040.USD","LU2750360641.GBP","LU0256863902.USD","LU2746668461.USD","SG9999017495.SGD","LU0417517546.SGD","LLYZ","LU0256863811.USD","LU2211815571.USD","LU0708995401.HKD","BK4585","SG9999015952.SGD","LU2417539215.USD","LU0683600562.USD","LU0882574139.USD","LU2237443382.USD","IE00BFSS7M15.SGD","LU2213496289.HKD","SG9999018857.SGD","LU2168564222.USD","LU1232071149.USD","LU1868837136.USD","LU0786609619.USD","LU0096364046.USD","SGXZ57979304.SGD","LU2896262040.SGD","IE00BK4W5M84.HKD","LU0234572021.USD","LU0316494557.USD","LU0109391861.USD","NVS","LU0823416689.USD","LU1061106388.HKD","IE00BFSS8Q28.SGD","LU1983299246.USD","LU0158827948.USD","LU0323591593.USD","LU1720051108.HKD","IE0002141913.USD","LU1868836914.USD","LU0823434740.USD","SG9999013999.USD","ELIL","LU2237443549.SGD","LU1035775433.USD","LU1804176565.USD","LU1988902786.USD","LU2237443622.USD","LU2112291526.USD","LU2756315318.SGD","LU2237443465.HKD","LU2746668974.SGD","LU0225283273.USD","LU1366192091.USD","SG9999014906.USD","LU2361044865.SGD","SG9999018865.SGD","LU2264538146.SGD","IE00B4R5TH58.HKD","LU1974910355.USD","LU0432979614.USD","LU0266013472.USD","LU2168564149.EUR","LU0320765059.SGD","LU2552382058.USD","BK4588","LU1868836757.USD","IE0004445015.USD","LU2108987350.USD","LU2087625088.SGD","LU2089283258.USD","LU2237443895.HKD","LU0882574055.USD","LU2237443978.SGD","LU2265009873.SGD","LU2271345857.HKD","LU0672654240.SGD","LU1280957306.USD","LU1629891620.HKD","IE00B775H168.HKD","LU0385154629.USD","SG9999001176.USD","LU2023250504.SGD","LU1551013342.USD","LU2168564065.EUR","LU1623119135.USD","LU0061475181.USD","LU1064131342.USD","LU2063271972.USD","LU0943347566.SGD","IE00BKPKM429.USD","LU2236285917.USD","LU2357305700.SGD","LU1093756325.SGD","SG9999015945.SGD","LU2361045086.USD","LU2602419157.SGD","BK4007","LU2028103732.USD","LU2089984988.USD","IE00BJJMRY28.SGD","LU0456855351.SGD","LLY","LU0353189763.USD","LU2468319806.SGD","IE00B4JS1V06.HKD","IE00B1XK9C88.USD","LU1145028129.USD","LU1868837300.USD","LU0109394709.USD","LU2491050154.USD","LU1023059063.AUD","LU1712237335.SGD","LU1069344957.HKD","LU1868836591.USD","LU0122379950.USD","BK4533","LU0689472784.USD","LU2462157665.USD","LU0238689110.USD","LU0889565916.HKD","SG9999014898.SGD","LU0964807845.USD","LU2237438978.USD","LU2456880835.USD","BK4581","LU0354030438.USD","SGXZ51526630.SGD","LLYX","LU0289739699.SGD","LU0320765992.SGD","IE00BJLML261.HKD","BK4599","LU2552382132.HKD","IE00B7KXQ091.USD","LU1720051017.SGD","LU0106261372.USD","LU0353189680.USD","LU1291159041.SGD","SG9999014880.SGD","LU0006306889.USD","LU2471134796.USD","LU0471298694.HKD","LU0203201768.USD","LU2168564495.EUR","LU0820561818.USD","SG9999001176.SGD","LU1323610961.USD","LU0354030511.USD","IE00BWXC8680.SGD","IE0009355771.USD","IE00BKDWB100.SGD","LU1093756168.USD","LU1814569148.SGD","LU2106854487.HKD","SG9999015978.USD","IE00BJT1NW94.SGD","LU1267930730.SGD","IE0005OL40V9.USD","LU0820562030.AUD","LU1551013425.SGD","LU2023250330.USD","LU2461242641.AUD","LU0787776722.HKD","LU0823434583.USD","LU0640476718.USD","LU0210536198.USD","BK4516","LU1917777945.USD","LU0158827781.USD","LU0058720904.USD","SG9999015986.USD","LU2089284900.SGD","LU0079474960.USD","IE00BN29S564.USD","LU0471298777.SGD","LU0094547139.USD","LU2168563687.JPY"],"gpt_icon":1},{"id":"2611486068","title":"超级大洗牌!跨国药企中国市场最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611486068?lang=zh_cn&edition=full","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份,跨国药企基本都披露了2025年业绩。礼来则以45%的增幅,营收达651.79亿美元成功反超默沙东,排名第三。而在中国市场,2025年1月,替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年,阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”,“销售一哥”的宝座每年轮流坐庄。此外,诺华已宣布在中国建立核药生产基地,以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国,才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","ASHS","BK4588","NVS","CQQQ","IE00BZ1G4Q59.USD","RHHBY","LU0154236417.USD","BK4504","CWEB","BK4585","NVOH","KWEB","LLY","LU0963586101.USD","IE00BKVL7J92.USD","NVO","DRAG","BK4599","MCHI","BK4007","BK4532","LU1093756325.SGD","AZN","NVOX","ASHR","LU1093756168.USD","BK4614"],"gpt_icon":1},{"id":"2609463565","title":"诺华制药2025财年实现净利润140.56亿美元,同比增加17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609463565","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609463565?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:01","pubTimestamp":1770393679,"startTime":"0","endTime":"0","summary":"2月7日,诺华制药公布财报,公告显示公司2025财年净利润为140.56亿美元,同比增加17.78%;其中营业收入为548.11亿美元,同比增加8.99%,每股基本收益为7.25美元。从资产负债表来看,诺华制药总负债690.20亿美元,其中短期债务57.84亿美元,资产负债比为0.01,流动比率为1.12。机构评级:截至2026年2月7日,当前有24家机构对诺华制药目标价做出预测,其中目标均价为145.67美元,其中最低目标价为109.51美元,最高目标价为175.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVS"],"gpt_icon":0},{"id":"2609554115","title":"诺华制药(NVS.US)全球首创自免新药在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609554115","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609554115?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:48","pubTimestamp":1770360522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,2月6日,CDE网站显示,诺华制药(NVS.US)的伊利尤单抗(ianalumab)在中国申报上市。伊利尤单抗是诺华收购(MorphoSys)获得的一款靶向B淋巴细胞活化因子受体(BAFF-R)的全人源单抗,具有耗竭B细胞和抑制BAFF-R的双重作用机制,可用于治疗干燥综合征、免疫性血小板减少症(ITP)、系统性红斑狼疮(SLE)等多种自免疾病。该药物是首个完成III期研究的抗BAFF-R抗体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","BK4007","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0009355771.USD","BK1574","BK1191","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD","01477","IE00BJT1NW94.SGD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4578","LU0208291251.USD","LU0070302665.USD","IE0002141913.USD","NVS"],"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347749?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问,中国不仅已经成为像诺华这样的大型制药公司极为重要的市场,同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日,诺华(NVS.US)首席执行官万思瀚在财报会上表达了上述观点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765489.SGD","LU0211331839.USD","IE0009355771.USD","BK4007","159837","IE0002141913.USD","IE00B2B36J28.USD","BK4578","IE00BJT1NW94.SGD","LU0070302665.USD","NVS","IE00BFTCPJ56.SGD","LU0208291251.USD","LABU","IE00B4R5TH58.HKD","BK4532","BK4588","BK4585","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2608013353","title":"仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2608013353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608013353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:48","pubTimestamp":1770191316,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,2月4日美股盘前,诺华制药公布2025年第四季度业绩。诺华公司预计今年利润将出现下滑,原因是公司的部分畅销药物将进一步受到仿制药竞争冲击。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击,首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华已承诺在美国新建七处生产设施,这是其斥资230亿美元扩大该国制造规模计划的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0070302665.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","BK4588","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4007","NVS","IE0009355771.USD","LU0320765489.SGD","LU0208291251.USD","01477","BK4532","LU0211331839.USD","IE0002141913.USD","BK4578","BK1191","IE00BFTCPJ56.SGD","BK1574"],"gpt_icon":0},{"id":"2608554332","title":"诺华:Q4核心净利润38.9亿美元,高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608554332","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608554332?lang=zh_cn&edition=full","pubTime":"2026-02-04 14:02","pubTimestamp":1770184975,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","BK4007","LU0208291251.USD","IE0002141913.USD","BK4532","LU0211331839.USD","IE00B2B36J28.USD","BK4578","LU0070302665.USD","BK4585","BK4588","IE0009355771.USD","NVS","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2608843538","title":"诺华可善挺(司库奇尤单抗)放射学阴性中轴型脊柱关节炎(nr-axSpA)适应症在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2608843538","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608843538?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:58","pubTimestamp":1770087491,"startTime":"0","endTime":"0","summary":"每经AI快讯,诺华集团公众号2月3日宣布,其创新生物制剂可善挺?(司库奇尤单抗)新适应症获得国家药品监督管理局批准,适用于治疗对非甾体类抗炎药(NSAID)应答不佳的活动性放射学阴性中轴型脊柱关节炎成人患者(其客观征象表现为C反应蛋白(CRP)升高和/或磁共振成像(MRI)证据)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602033639802448.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033639802448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJT1NW94.SGD","BK4578","BK4007","LU0208291251.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0070302665.USD","IE0009355771.USD","LU0320765489.SGD","NVS","IE00BJJMRZ35.SGD","BK4585","BK4532"],"gpt_icon":0},{"id":"2606711156","title":"诺华制药(NVS.US)siRNA疗法“英克司兰”获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711156","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606711156?lang=zh_cn&edition=full","pubTime":"2026-01-28 21:15","pubTimestamp":1769606154,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,1月28日,诺华制药(NVS.US)宣布其全球首创小干扰RNA降胆固醇药物乐可为®(英克司兰钠注射液)获中国国家药品监督管理局(NMPA)批准,作为饮食的辅助疗法,单药用于成人原发性高胆固醇血症(非家族性)或混合型血脂异常的患者,以降低低密度脂蛋白胆固醇(LDL-C)。英克司兰在此前已获批的与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药适应症的基础上,进一步覆盖了更多有需要的血脂异常患者。作为全球首款也是目前唯一获批的一款靶向PCSK9的小干扰RNA降胆固醇药物,英克司兰一年两针的给药方式,有望提升治疗依从性及LDL-C的长期达标率,助力实现血脂的长期规范化管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","BK1574","01477","BK4007","IE0002141913.USD","IE0009355771.USD","LU0211331839.USD","BK4588","NVS","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK1191","IE00B4R5TH58.HKD","BK4585","BK4532","LU0320765489.SGD","LU0070302665.USD","BK4578"],"gpt_icon":0},{"id":"1158049890","title":"财报前瞻|诺华本季度营收预计增5.72%,机构观点以偏积极为主","url":"https://stock-news.laohu8.com/highlight/detail?id=1158049890","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158049890?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:02","pubTimestamp":1769565747,"startTime":"0","endTime":"0","summary":"诺华将在2026年02月04日发布最新季度财报,市场关注收入与盈利的同步扩张及核心产品组合的提质与优化带来的利润改善与现金流稳健性。市场一致预期本季度诺华总收入为135.44亿美元,同比增5.72%;调整后每股收益为1.96美元,同比增8.26%;息税前利润为45.89亿美元,同比增7.12%。目前未形成针对本季度毛利率与净利率的公开一致预测,原因是机构在口径上存在差异且尚无统一披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|诺华本季度营收预计增5.72%,机构观点以偏积极为主","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"gpt_icon":0},{"id":"2605247377","title":"直击达沃斯丨医渡科技(02158)、文莱卫生部、诺华基金会宣布启动AI驱动的国家级心血管疾病防控项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2605247377","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605247377?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:30","pubTimestamp":1769160649,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,2026年世界经济论坛年会上,诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作:诺华基金会、文莱卫生部、医渡科技旗下EVYD公司将联合实施数智驱动的心血管疾病防控项目——CARDIO4Cities。当前,心血管疾病及其他非传染性疾病已成为全球死亡的主要原因,占比超70%。文莱国内心血管疾病更是主要死亡原因,给当地公共卫生体系带来持续压力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE0002141913.USD","IE0009355771.USD","LU0320765489.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","NVS","LU0211331839.USD","BK4007","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4578","LU0208291251.USD","BK1518","BK1617","LU0070302665.USD","BK1189","02158"],"gpt_icon":0},{"id":"2603691636","title":"FDA概述细胞/基因疗法CMC灵活性 可能对诺华与辉瑞有利","url":"https://stock-news.laohu8.com/highlight/detail?id=2603691636","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603691636?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:01","pubTimestamp":1768320060,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)详细说明了为加速细胞与基因治疗开发而定制的生产与控制让步措施,同时保持标准,这可能对诺华(NVS)和辉瑞(PFE)等开发商构成潜在利好。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-14/doc-inhheupf5646437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4592","BK4532","SG9999002232.USD","LU0882574139.USD","LU1363072403.SGD","LU0058720904.USD","LU2237443549.SGD","LU1894683264.USD","IE00BHPRN162.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","IE00BZ1G4Q59.USD","LU2237443622.USD","SG9999011175.SGD","LU2237443978.SGD","LU0321505868.SGD","IE00BBT3K403.USD","IE0002270589.USD","LU1066051498.USD","BK4585","NVS","LU0306807586.USD","BK4007","LU0225284248.USD","IE00B4R5TH58.HKD","LU2746668974.SGD","LU2746668461.USD","LU0267386448.USD","IE00BKVL7J92.USD","LU0868494617.USD","IE000M9KFDE8.USD","LU1883839398.USD","IE00BFXG1179.USD","SG9999002224.SGD","PFE","LU1066053197.SGD","LU2237443895.HKD","SG9999013999.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4588","IE0002141913.USD","LU0149725797.USD","LU0321505439.SGD","LU1023059063.AUD","IE0009355771.USD","BK4578","LU0122379950.USD","LU0320765489.SGD","BK4533","LU2237443465.HKD","LU2237443382.USD","LU0289739699.SGD","LU0306806265.USD","BK4599","LU0234572021.USD","BK4568","LU0971096721.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0211331839.USD","LU0225771236.USD","SG9999003800.SGD","LU1894683348.USD","LU0070302665.USD","BK4550","LU0456855351.SGD","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU1057294990.SGD","SGXZ57979304.SGD","SG9999001176.USD","BK4581","IE00BJT1NW94.SGD","BK4006","LU0208291251.USD","IE00B19Z3581.USD","BK4534","SG9999001176.SGD"],"gpt_icon":0},{"id":"2602640541","title":"赛诺神经与诺华签署17亿美元许可协议 合作开发阿尔茨海默病治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2602640541","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602640541?lang=zh_cn&edition=full","pubTime":"2026-01-12 23:24","pubTimestamp":1768231440,"startTime":"0","endTime":"0","summary":"生物科技企业赛诺神经制药公司于周一宣布,已与瑞士制药巨头诺华达成一项价值近 17 亿美元的许可协议,双方将合作开发用于治疗阿尔茨海默病的潜在抗体疗法。 通过这项协议,诺华将获得赛诺神经一项核心专有技术的使用权,该技术旨在优化药物向大脑的递送效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhf8113709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJJMRZ35.SGD","BK4585","BK4578","LU0070302665.USD","LU0320765489.SGD","IE0009355771.USD","NVS","IE00B2B36J28.USD","LU0211331839.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4588","IE0002141913.USD","BK4532","BK4007","IE00BFTCPJ56.SGD","LU0208291251.USD"],"gpt_icon":0},{"id":"2602592441","title":"中晟全肽与诺华就一款放射性配体疗法资产签署全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2602592441","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602592441?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205749,"startTime":"0","endTime":"0","summary":"每经AI快讯,湖南中晟全肽生物科技股份有限公司1月12日通过公众号宣布,公司已与诺华就放射性配体疗法领域一款未披露的多肽类资产达成全球授权与合作协议。根据协议,诺华获得该资产的全球独家授权,并将主导后续所有研发及商业化相关工作。根据协议条款,中晟全肽将获得5000万美元首付款,并有资格获得后续研发、监管及销售里程碑付款,同时有权就未来全球净销售额享受分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601123615775823.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601123615775823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJT1NW94.SGD","BK4578","BK4007","LU0208291251.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0070302665.USD","IE0009355771.USD","LU0320765489.SGD","NVS","IE00BJJMRZ35.SGD","BK4585","BK4532"],"gpt_icon":0},{"id":"2602322575","title":"超1亿美元!蛋白降解剂“吸金”,强生、诺华、谷歌都来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2602322575","media":"医药魔方","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602322575?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:43","pubTimestamp":1767951793,"startTime":"0","endTime":"0","summary":"1月9日,致力于开发细胞外蛋白降解剂的EpiBiologics宣布完成1.07亿美元B轮融资,本轮融资由Google Ventures及Johnson & Johnson Innovation领投,Novartis Venture Fund等新投资者及Polaris Partners等现有投资者跟投。TrainTAC利用广泛的内化受体将膜蛋白和可溶性细胞外蛋白转运到溶酶体进行降解。EpiBiologics正在基于EpiTAC开发first-in-class及best-in-class靶向疗法,涉及肿瘤、免疫疾病等领域。在2025年AACR大会上,公司首次公布了c-Met EpiTAC双特异性抗体降解剂的临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109183655a706f830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109183655a706f830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0302445910.USD","LU2168563687.JPY","LU2764262908.HKD","LU0211328371.USD","LU0077335932.USD","LU2362540622.SGD","IE00BGHQF631.EUR","BK4077","LU0957808578.USD","LU1934455194.USD","LU2213496289.HKD","LU1069347547.HKD","LU0353189763.USD","IE0009356076.USD","LU2505996681.GBP","GB00B4QBRK32.GBP","IE00B7KXQ091.USD","IE00BBT3K403.USD","LU0154236417.USD","LU0784383803.USD","IE00BJJMRZ35.SGD","IE000M9KFDE8.USD","IE0004445015.USD","LU0345768740.USD","BK4554","LU0976567544.SGD","LU1868836914.USD","LU0251131958.USD","IE00B4R5TH58.HKD","LU0130103400.USD","LU1791710582.SGD","LU0784384876.USD","IE00B1XK9C88.USD","LU2360032135.SGD","BK4504","LU0070302665.USD","LU2326559502.SGD","GB00B4LPDJ14.GBP","LU2028103732.USD","LU0708995401.HKD","IE00B19Z8W00.USD","LU0444971666.USD","IE00BFMHRM44.USD","IE00BQXX3C00.GBP","LU1935042991.SGD","LU0109391861.USD","LU1951200564.SGD","LU0130517989.USD","LU0203345920.USD","LU0787776722.HKD","LU1935042215.USD","LU0072462426.USD","LU0345774391.USD","LU0661504455.SGD","LU1244550221.USD","IE00BLSP4452.SGD","LU1815333072.USD","LU0029864427.USD","LU2764263203.CNY","IE00BJTD4N35.SGD","LU1551013342.USD","LU0994945656.USD","LU0234570918.USD","SGXZ31699556.SGD","LU1280957306.USD","LU1366333091.USD","LU0122379950.USD","SG9999002224.SGD","LU0070217475.USD","LU2065171402.SGD","LU2471134879.HKD","LU1791710400.SGD","LU0256863902.USD","LU2491050154.USD","LU1571399168.USD","BK4579","LU1670627923.USD","LU2271345857.HKD","LU0203202063.USD","LU1267930730.SGD","LU2264538146.SGD","LU1691799644.USD","LU0672654240.SGD","LU1935043536.SGD","BK4574","LU2065171311.SGD","SG9999015945.SGD","LU0354030438.USD","BK4533","SG9999017495.SGD","LU2750360641.GBP","LU2592432038.USD","LU2430703251.USD","LU1852331112.SGD","LU1323610961.USD","JNJ","LU0788109477.HKD","LU0882574055.USD","BK4561","LU2125154935.USD","LU2357305700.SGD","LU0052756011.USD","LU0965509010.AUD","LU1506573853.SGD","LU1732799900.SGD","LU2265009873.SGD","LU2168564222.USD","NVS","LU1923623000.USD","LU2168564149.EUR","LU2404859667.USD","LU2097344431.USD","LU0861579265.USD","LU2458330169.SGD","LU0795875086.SGD","LU1032466523.USD","IE00BZ1G4Q59.USD","LU0466842654.USD","LU0314106906.USD","LU0444973449.USD","LU1720051017.SGD","LU0130102774.USD","LU1929549753.HKD","LU0310799852.SGD","LU1974910355.USD","BK4566","IE00BFXG0V08.USD","LU0477156797.USD","LU0096362180.USD","IE00BJT1NW94.SGD","IE0034235303.USD","LU0006306889.USD","LU0289941410.SGD","SG9999015978.USD","LU0545039389.USD","IE00B19Z8X17.USD","LU2505996509.AUD","LU1043141396.HKD","LU2237438978.USD","IE00BMPRXQ63.HKD","LU2552382215.SGD","LU2111349929.HKD","BK4534","IE0002270589.USD","LU1066051225.USD","IE00BKDWB100.SGD","LU1551013425.SGD","LU0267386448.USD","IE0034235188.USD","BK4543","LU2756315318.SGD","LU0187121727.USD","LU0106261372.USD","LU0208291251.USD","GOOGL","LU0432979614.USD","LU0477156953.USD","IE00B775SV38.USD","LU0080751232.USD","IE0001KFT4U8.USD","LU2112291526.USD","BK4007","LU1221951046.USD","LU1430594728.SGD","LU2347655156.SGD","BK4585","LU0312595415.SGD","LU2065169927.USD","LU0345770308.USD","LU1989764748.USD","LU0868494708.USD","BK4581","LU0310800379.SGD","BK4592","LU1267930573.SGD","LU1023059063.AUD","LU0114720955.EUR","LU0942090050.USD","LU1720051108.HKD","LU0234572021.USD","LU1496350171.SGD","LU0058720904.USD","LU1633808545.USD","LU0345769631.USD","LU0251132253.USD","BK4514","LU2089984988.USD","LU0320765646.SGD","IE00B42XCP33.USD","LU1642822529.SGD","LU2491049909.HKD","LU0496365809.HKD","LU0889566641.SGD","BK4568","LU1989764664.SGD","LU0742534661.SGD","LU1127390331.HKD","IE00BK4W5M84.HKD","LU0109392836.USD","LU0889565833.HKD","LU0557290698.USD","LU2430703178.SGD","LU2054465674.USD","LU1267930813.SGD","SG9999000418.SGD","LU1153585028.USD","LU1489326972.SGD","LU2750360997.AUD","LU2023251221.USD","LU0225283273.USD","LU1035775433.USD","LU0048573561.USD","LU2361044865.SGD","LU0323591593.USD","LU0289739699.SGD","LU1066053197.SGD","LU0417517546.SGD","LU1839511570.USD","LU2211815571.USD","LU0158827948.USD","BK4587","LU1244550494.USD","LU1064131342.USD","IE00BSNM7G36.USD","LU0251142724.SGD","LU0265550359.USD","LU1059921491.USD","LU1804176565.USD","LU2097829019.USD","LU2456880835.USD","LU0345768153.USD","LU1046421795.USD","LU2420271590.USD","LU2463028550.USD","LU1121112475.USD","LU1043141123.HKD","LU2468319806.SGD","LU2087625088.SGD","IE00BFSS7M15.SGD","LU1235294995.USD","LU2237443382.USD","LU2237443978.SGD","LU0342679015.USD","LU2487616109.SGD","LU0345770993.USD","LU2108987350.USD","GOOG","SG9999001440.SGD","LU0276348264.USD","LU1496350502.SGD","SGXZ51526630.SGD","LU1935042488.USD","LU2092937148.SGD","LU0096364046.USD","IE00BFTCPJ56.SGD","SG9999014914.USD","IE00BFXG1179.USD","LU1162221912.USD","BK4612","IE0009355771.USD","IE00B5949003.HKD","LU2237443549.SGD","LU0107464264.USD","LU1732800096.USD","LU2362541273.HKD","LU0061474960.USD","SG9999002232.USD","LU0127658192.USD","SG9999018857.SGD","LU1718418525.SGD","IE00B7SZLL34.SGD","LU1435385759.SGD","IE00BLSP4239.USD","LU2361045086.USD","LU2471134952.CNY","IE00B4JS1V06.HKD","LU0256863811.USD","LU2023250843.SGD","IE0002141913.USD","IE00BVYPNW00.USD","IE00B2B36J28.USD","LU2089283258.USD","LU2286300806.USD","LU1548497426.USD","LU0965509101.SGD","LU0648000940.SGD","SGXZ81514606.USD","LU2125154778.USD","LU1988902786.USD","IE00B3T34201.USD","LU0820562030.AUD","IE00B775H168.HKD","LU0068578508.USD","LU0158827781.USD","LU2237443622.USD","LU0348723411.USD","LU0345774631.USD","IE00B19Z3581.USD","LU0528227936.USD","LU0823421416.USD","LU0949170772.SGD","LU1035773651.USD","LU2247934214.USD","BK4553","BK4602","IE00B3S45H60.SGD","LU0648001328.SGD","LU0128525689.USD","LU0124676726.USD","LU0683600562.USD","LU1066051498.USD","LU1366192091.USD","LU1803068979.SGD","IE00BVYPNV92.GBP","LU0784385840.USD","SG9999014898.SGD","LU0353189680.USD","BK4525","LU0690374961.EUR","LU0238689110.USD","LU1935043023.USD","LU0053666078.USD","LU0553294199.USD","LU0097036916.USD","LU0912757837.SGD","LU2242650005.HKD","LU0784385170.HKD","LU1196500208.SGD","LU2023250330.USD","IE00BN8TJ469.HKD","LU0203201768.USD","LU0823421333.USD","LU2471134523.USD","LU0690374615.EUR","LU1221951129.SGD","LU1074936037.SGD","LU1201861249.SGD","LU1066051811.HKD","LU0823434740.USD","LU1914381329.SGD","LU1674673691.USD","LU1261432733.SGD","LU2063271972.USD","LU0985320562.USD","BK4503","LU2552382058.USD","IE00B19Z9505.USD","LU0048584097.USD","LU0965509283.SGD","LU1815336760.USD","IE0005OL40V9.USD","IE00BJLML261.HKD","LU1303367103.USD","LU1116320901.HKD","LU2133065610.SGD","LU0211326755.USD","LU1674673428.USD","BK4588","BK4548","IE00B1BXHZ80.USD","LU1868836591.USD","IE00BJJMRY28.SGD","LU2129689605.HKD","LU1037948541.HKD","LU0082616367.USD","LU0354030511.USD","LU1629891620.HKD","LU2242649171.HKD","IE00BHPRN162.USD","IE00BWXC8680.SGD","LU1267930490.SGD","LU0211331839.USD","IE00BJTD4V19.USD","LU0795875169.SGD","LU1868836757.USD","LU0198837287.USD","SG9999014880.SGD","LU2746668461.USD","BK4507","SGXZ99366536.SGD","LU0964807845.USD","IE0004445239.USD","LU0320765059.SGD","IE00BFSS8Q28.SGD","SG9999015986.USD","LU0170899867.USD","BK4532","LU2896262040.SGD","LU2237443465.HKD","IE00BZ199S13.USD","LU2381873111.SGD","LU2417539215.USD","BK4559","LU0708994859.HKD","LU0310800965.SGD","LU2097344357.USD","IE0004091025.USD","LU1934455863.HKD","LU1057294990.SGD","LU1868837136.USD","LU1880398471.USD","LU2098885051.SGD","LU1823568750.SGD","LU0738911758.USD","LU1803068623.USD","LU1069344957.HKD","LU2250418816.HKD","LU0079474960.USD","LU0980610538.SGD","LU0203347892.USD","LU2129689514.USD","LU0056508442.USD","IE0004086264.USD","LU0786609619.USD","LU2860962120.EUR","LU2764263039.SGD","LU0820561909.HKD","LU0314104364.USD","LU2360106780.USD","LU2244417387.USD","LU1894683348.USD","LU0689472784.USD","LU0265550946.USD","IE00BKVL7J92.USD","LU2720916845.USD","USJW.SI","LU0061474705.USD","LU0476273544.USD","LU2237443895.HKD","LU2087621335.USD","LU1201861165.SGD","LU2552382132.HKD","LU0094547139.USD","LU0949170426.SGD","LU1934455277.USD","LU2756315664.SGD","LU1084165304.USD","LU2168564065.EUR","LU0719512351.SGD","LU2404859741.USD","LU1880398554.USD","LU2746668974.SGD","LU0175139822.USD","LU0308772762.SGD","LU2191332357.HKD","LU2023250504.SGD","LU2168564495.EUR","LU2065170008.USD","LU1585245621.USD","LU0211326839.USD","BK4578","LU2129689431.USD","IE00BN29S564.USD","LU0878866978.SGD","LU0965508806.USD","LU2458330243.SGD","LU0011850046.USD","LU0320765489.SGD","LU0289960550.SGD","LU0210528500.USD","LU2491050071.SGD","IE00B5TLWC47.USD","LU0689626769.HKD","IE00BYQQ9H92.USD","LU0149725797.USD","IE00B19Z3B42.SGD","LU2462157665.USD","BK4550","LU0316494557.USD","LU0345769128.USD","IE00BK4W5L77.USD","LU1061106388.HKD","IE00BJJMRX11.SGD","LU1119994496.HKD","LU0868494617.USD","LU1244550577.SGD","SG9999014906.USD","LU1868837300.USD","LU1699723380.USD","LU2275660780.HKD","LU0433182093.SGD","LU0061475181.USD","IE00BMPRXR70.SGD","SG9999001077.SGD","BK4538","LU2106854487.HKD","LU2430703095.HKD","LU0640476718.USD","LU0823434583.USD","LU1145028129.USD","LU2089284900.SGD","IE00BQXX3D17.EUR","LU1951198990.SGD","BK4576","LU1894683264.USD","LU2092627202.USD","LU0426412945.USD","LU2362541513.USD","LU2543165471.USD","LU2461242641.AUD","LU0882574139.USD","LU0426417589.USD","LU0456855351.SGD","LU0494093205.USD","LU0215105999.USD","LU1267930227.SGD","LU1778281490.HKD","BK4527","LU1037948897.HKD","SG9999018865.SGD","LU1670628061.USD","LU2403377893.USD","LU1814569148.SGD","IE00BQXX3F31.USD","LU0211327993.USD","LU0642271901.SGD","LU2361044949.HKD","LU0157215616.USD","LU0957791311.USD","IE00BKPKM429.USD","LU1429558221.USD","LU0792757196.USD","LU2471134796.USD","LU1316542783.SGD","LU1003077747.HKD","LU0128525929.USD","IE00B3PB1722.GBP","LU1032955483.USD","LU0130518102.USD","IE00BDGV0183.EUR","SG9999015952.SGD","LU0985489474.SGD","LU0820561818.USD","IE00BMPRXN33.USD","LU2602419157.SGD","LU2077746001.SGD","LU1116320737.USD","LU0098860793.USD","LU1917777945.USD","LU0210533765.USD","BK4598","LU1301847155.USD","LU2236285917.USD","LU0210536198.USD","BK4573","LU0724617625.USD","LU0943347566.SGD","LU1232071149.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":-0.0245},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.2426},{"period":"6month","weight":0.2864},{"period":"1year","weight":0.4086},{"period":"ytd","weight":0.1807}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立,为股份公司。公司是一家创新医药公司,从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域,包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":0.000058},{"month":4,"riseRate":0.72,"avgChangeRate":0.018717},{"month":5,"riseRate":0.68,"avgChangeRate":0.009252},{"month":6,"riseRate":0.576923,"avgChangeRate":0.011998},{"month":7,"riseRate":0.692308,"avgChangeRate":0.011407},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}